Abstract
Hepatitis A virus (HAV) superinfection is associated with a high risk of liver failure and death in patients with underlying chronic liver disease. HAV vaccination is effective and safe, although the vaccine is less immunogenic in patients with advanced liver disease. Despite recommendations to immunize patients with chronic liver disease, rates of HAV vaccination remain low. thus highlighting the need for public health programs to increase awareness about HAV vaccination.
| Original language | English |
|---|---|
| Pages (from-to) | 49-53 |
| Number of pages | 5 |
| Journal | Current Hepatitis Reports |
| Volume | 5 |
| Issue number | 2 |
| DOIs | |
| State | Published - May 2006 |
| Externally published | Yes |